A Study of LY3867070 in Healthy Participants
Completed · Phase 1 · NCT07021547
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $2.8M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 141
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3867070 (drug), Placebo (drug)
- Dates
- Started 2025-05-27; completion 2026-09-30
- Results posted
- Not yet
The purpose of this study is to evaluate how well LY3867070 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $2.8M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $2.6M
- Covance Clinical Research Unit Inc $190,453
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.